Inhalation anesthetics augment oxidant-induced pulmonary vasoconstriction

Evidence for a membrane effect

Jay R. Shayevitz, R. J. Traystman, N. F. Adkinson, A. M. Sciuto, G. H. Gurtner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Inhalational anesthetics 'fluidize' biologic membranes. Since arachidonate metabolism also occurs in cell membranes, anesthetic agents may modify arachidonic acid metiator production. The authors used the isolated perfused rabbit lung preparation to examine the effects of inhalational anesthetics on the production of arachidonate mediators. The oxidant tert-butyl-hydroperoxide (t-bu-OOH) is known to cause pulmonary vasoconstriction by causing increased production of thromboxane A2 (TxA2). The authors administered three anesthetics (halthane, cyclpropane, and nitrous oxide) of widely different potencies, at different dosages, each to three different groups of preparations and challenged the lungs at each anesthetic dose with t-bu-OOH. They found a dose-related augmentation of the pulmonary vasopressor response to t-bu-OOH. Preparations given t-bu-OOH alone showed no change in response over time. Lungs perfused with indomethacin (5 μg· ml-1 in Krebs-Henseleit buffer), ventilated with cyclopropane (2 MAC), and challenged with t-bu-OOH showed almost complete inhibition of the response to t-bu-OOH. Indomethacin at this concentration is a specific inhibitor of cyclooxygenase. The authors also demonstrated significantly increased perfusate levels of thromboxane B2 (TxB2), the inactive metabolite of TxA2, after oxidant challenge during exposure to 2% halothane compared with TxB2 levels before halothane exposure. The authors believe that the augmented pressor response and mediator production occur because of increased substrate (arachidonic acid) availability induced by anesthetic agent.

Original languageEnglish (US)
Pages (from-to)624-632
Number of pages9
JournalAnesthesiology
Volume63
Issue number6
StatePublished - 1985
Externally publishedYes

Fingerprint

Inhalation Anesthetics
Vasoconstriction
Oxidants
Anesthetics
Lung
Membranes
Thromboxane B2
Thromboxane A2
Halothane
Arachidonic Acid
Indomethacin
tert-Butylhydroperoxide
Cyclooxygenase Inhibitors
Nitrous Oxide
Cell Membrane
Rabbits

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Shayevitz, J. R., Traystman, R. J., Adkinson, N. F., Sciuto, A. M., & Gurtner, G. H. (1985). Inhalation anesthetics augment oxidant-induced pulmonary vasoconstriction: Evidence for a membrane effect. Anesthesiology, 63(6), 624-632.

Inhalation anesthetics augment oxidant-induced pulmonary vasoconstriction : Evidence for a membrane effect. / Shayevitz, Jay R.; Traystman, R. J.; Adkinson, N. F.; Sciuto, A. M.; Gurtner, G. H.

In: Anesthesiology, Vol. 63, No. 6, 1985, p. 624-632.

Research output: Contribution to journalArticle

Shayevitz, JR, Traystman, RJ, Adkinson, NF, Sciuto, AM & Gurtner, GH 1985, 'Inhalation anesthetics augment oxidant-induced pulmonary vasoconstriction: Evidence for a membrane effect', Anesthesiology, vol. 63, no. 6, pp. 624-632.
Shayevitz, Jay R. ; Traystman, R. J. ; Adkinson, N. F. ; Sciuto, A. M. ; Gurtner, G. H. / Inhalation anesthetics augment oxidant-induced pulmonary vasoconstriction : Evidence for a membrane effect. In: Anesthesiology. 1985 ; Vol. 63, No. 6. pp. 624-632.
@article{0d162b3dad3c4971b6ae9475c33c213c,
title = "Inhalation anesthetics augment oxidant-induced pulmonary vasoconstriction: Evidence for a membrane effect",
abstract = "Inhalational anesthetics 'fluidize' biologic membranes. Since arachidonate metabolism also occurs in cell membranes, anesthetic agents may modify arachidonic acid metiator production. The authors used the isolated perfused rabbit lung preparation to examine the effects of inhalational anesthetics on the production of arachidonate mediators. The oxidant tert-butyl-hydroperoxide (t-bu-OOH) is known to cause pulmonary vasoconstriction by causing increased production of thromboxane A2 (TxA2). The authors administered three anesthetics (halthane, cyclpropane, and nitrous oxide) of widely different potencies, at different dosages, each to three different groups of preparations and challenged the lungs at each anesthetic dose with t-bu-OOH. They found a dose-related augmentation of the pulmonary vasopressor response to t-bu-OOH. Preparations given t-bu-OOH alone showed no change in response over time. Lungs perfused with indomethacin (5 μg· ml-1 in Krebs-Henseleit buffer), ventilated with cyclopropane (2 MAC), and challenged with t-bu-OOH showed almost complete inhibition of the response to t-bu-OOH. Indomethacin at this concentration is a specific inhibitor of cyclooxygenase. The authors also demonstrated significantly increased perfusate levels of thromboxane B2 (TxB2), the inactive metabolite of TxA2, after oxidant challenge during exposure to 2{\%} halothane compared with TxB2 levels before halothane exposure. The authors believe that the augmented pressor response and mediator production occur because of increased substrate (arachidonic acid) availability induced by anesthetic agent.",
author = "Shayevitz, {Jay R.} and Traystman, {R. J.} and Adkinson, {N. F.} and Sciuto, {A. M.} and Gurtner, {G. H.}",
year = "1985",
language = "English (US)",
volume = "63",
pages = "624--632",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Inhalation anesthetics augment oxidant-induced pulmonary vasoconstriction

T2 - Evidence for a membrane effect

AU - Shayevitz, Jay R.

AU - Traystman, R. J.

AU - Adkinson, N. F.

AU - Sciuto, A. M.

AU - Gurtner, G. H.

PY - 1985

Y1 - 1985

N2 - Inhalational anesthetics 'fluidize' biologic membranes. Since arachidonate metabolism also occurs in cell membranes, anesthetic agents may modify arachidonic acid metiator production. The authors used the isolated perfused rabbit lung preparation to examine the effects of inhalational anesthetics on the production of arachidonate mediators. The oxidant tert-butyl-hydroperoxide (t-bu-OOH) is known to cause pulmonary vasoconstriction by causing increased production of thromboxane A2 (TxA2). The authors administered three anesthetics (halthane, cyclpropane, and nitrous oxide) of widely different potencies, at different dosages, each to three different groups of preparations and challenged the lungs at each anesthetic dose with t-bu-OOH. They found a dose-related augmentation of the pulmonary vasopressor response to t-bu-OOH. Preparations given t-bu-OOH alone showed no change in response over time. Lungs perfused with indomethacin (5 μg· ml-1 in Krebs-Henseleit buffer), ventilated with cyclopropane (2 MAC), and challenged with t-bu-OOH showed almost complete inhibition of the response to t-bu-OOH. Indomethacin at this concentration is a specific inhibitor of cyclooxygenase. The authors also demonstrated significantly increased perfusate levels of thromboxane B2 (TxB2), the inactive metabolite of TxA2, after oxidant challenge during exposure to 2% halothane compared with TxB2 levels before halothane exposure. The authors believe that the augmented pressor response and mediator production occur because of increased substrate (arachidonic acid) availability induced by anesthetic agent.

AB - Inhalational anesthetics 'fluidize' biologic membranes. Since arachidonate metabolism also occurs in cell membranes, anesthetic agents may modify arachidonic acid metiator production. The authors used the isolated perfused rabbit lung preparation to examine the effects of inhalational anesthetics on the production of arachidonate mediators. The oxidant tert-butyl-hydroperoxide (t-bu-OOH) is known to cause pulmonary vasoconstriction by causing increased production of thromboxane A2 (TxA2). The authors administered three anesthetics (halthane, cyclpropane, and nitrous oxide) of widely different potencies, at different dosages, each to three different groups of preparations and challenged the lungs at each anesthetic dose with t-bu-OOH. They found a dose-related augmentation of the pulmonary vasopressor response to t-bu-OOH. Preparations given t-bu-OOH alone showed no change in response over time. Lungs perfused with indomethacin (5 μg· ml-1 in Krebs-Henseleit buffer), ventilated with cyclopropane (2 MAC), and challenged with t-bu-OOH showed almost complete inhibition of the response to t-bu-OOH. Indomethacin at this concentration is a specific inhibitor of cyclooxygenase. The authors also demonstrated significantly increased perfusate levels of thromboxane B2 (TxB2), the inactive metabolite of TxA2, after oxidant challenge during exposure to 2% halothane compared with TxB2 levels before halothane exposure. The authors believe that the augmented pressor response and mediator production occur because of increased substrate (arachidonic acid) availability induced by anesthetic agent.

UR - http://www.scopus.com/inward/record.url?scp=0022353249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022353249&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 624

EP - 632

JO - Anesthesiology

JF - Anesthesiology

SN - 0003-3022

IS - 6

ER -